Table 1.
Clinical and demographic summary of ccRCC cohorts.
| Variables | TCC ccRCC patients, no. (%) (n = 105) | CPTAC-3 ccRCC patients, no. (%) (n = 110) | TCGA-KIRC ccRCC patients, no. (%) (n = 441) |
|---|---|---|---|
| Sex | |||
| Female | 35 (33.3) | 30 (27.3) | 153 (34.7) |
| Male | 70 (66.7) | 80 (72.7) | 288 (65.3) |
| Race | |||
| Asian Indian or Pakistani | 2 (1.9) | 1 (0.01) | 7 (1.6) |
| Black | 3 (2.9) | 1 (0.01) | 30 (6.8) |
| Other | 7 (6.7) | — | — |
| White | 93 (88.5) | 61 (55.5) | 397 (90.0) |
| Not reported | — | 47 (42.7) | 7 (1.6) |
| Tumor laterality | |||
| Left | 62 (59.0) | NA | NA |
| Right | 43 (41.0) | NA | NA |
| Surgery type | |||
| Partial nephrectomy | 22 (21.0) | NA | NA |
| Radical nephrectomy | 65 (61.9) | NA | NA |
| Radical nephrectomy with thrombectomy | 18 (17.1) | NA | NA |
| Fuhrman nuclear grade | |||
| 1 | 0 | 7 (6.4) | 9 (2.0) |
| 2 | 30 (28.6) | 53 (48.2) | 182 (41.3) |
| 3 | 62 (59.0) | 41 (37.3) | 179 (40.6) |
| 4 | 13 (12.4) | 9 (8.2) | 68 (15.4) |
| Not reported | — | — | 3 (0.7) |
| pT | |||
| T1 | 31 (29.5) | 52 (47.3) | 211 (47.8) |
| T2 | 3 (2.9) | 13 (11.8) | 58 (13.2) |
| T3+T4 | 70 (66.7) | 45 (40.9) | 172 (39.0) |
| Not reported | 1 (1.0) | — | — |
| pN | |||
| N0 | 27 (25.7) | 16 (14.5) | 203 (46.0) |
| N1 | 5 (4.8) | 4 (3.6) | 13 (2.9) |
| NX | 73 (69.5) | 89 (81.9) | 225 (51.0) |
| pM | |||
| M0 | — | 34 (30.9) | 353 (80.0) |
| M1 | 23 (21.9) | 3 (2.7) | 73 (16.6) |
| MX | 82 (78.1) | — | 14 (3.2) |
| Not reported | — | 73 (66.4) | 1 (0.2) |
| Sarcomatoid status | |||
| No | 99 (94.3) | NA | NA |
| Yes | 6 (5.7) | NA | NA |
| Vitality | |||
| Alive | 82 (78.1) | 96 (87.3) | 118 (83.1) |
| Dead | 23 (21.9) | 14 (12.7) | 24 (16.9) |
| Age at surgery (yr) | Age at diagnosis (yr) | Age at diagnosis (yr) | |
| Median (range) | 65 (36–87) | 60 (30–89) | NA |
| Pathological tumor size (cm) | |||
| Median (range) | 6.0 (1.3–17.5) | 6.4 (1.0–16.0) | NA |
| % EGFR splice variant alpha | |||
| Median (range) | 1.01 (0.00–41.33) | NA | NA |
| BAP1 mutation | |||
| Wild type | 61 (58.1) | 93 (84.5) | 372 (84.4) |
| Alteration | 4 (3.8) | 17 (15.5) | 47 (10.6) |
| Not reported | 40 (38.1) | — | 22 (5.0) |
| KDM5C mutation | |||
| Wild type | 56 (53.3) | 91 (82.7) | 389 (88.2) |
| Alteration | 9 (8.6) | 19 (17.3) | 30 (6.8) |
| Not reported | 40 (38.1) | — | 22 (5.0) |
| MTOR mutation | |||
| Wild type | 62 (59.0) | 104 (94.5) | 392 (88.9) |
| Alteration | 3 (2.9) | 6 (5.5) | 27 (6.1) |
| Not reported | 40 (38.1) | — | 22 (5.0) |
| PBRM1 mutation | |||
| Wild type | 41 (39.0) | 66 (60.0) | 258 (58.5) |
| Alteration | 24 (22.9) | 44 (40.0) | 161 (36.5) |
| Not reported | 40 (38.1) | — | 22 (5.0) |
| PTEN mutation | |||
| Wild type | 60 (57.1) | 105 (95.5) | 399 (90.5) |
| Alteration | 5 (4.8) | 5 (4.5) | 20 (4.5) |
| Not reported | 40 (38.1) | — | 22 (5.0) |
| SETD2 mutation | |||
| Wild type | 55 (52.4) | 95 (86.4) | 360 (81.6) |
| Alteration | 10 (9.5) | 15 (13.6) | 59 (13.4) |
| Not reported | 40 (38.1) | — | 22 (5.0) |
| TP53 mutation | |||
| Wild type | 61 (58.1) | 104 (94.5) | 408 (92.5) |
| Alteration | 4 (3.8) | 6 (5.5) | 11 (2.5) |
| Not reported | 40 (38.1) | — | 22 (5.0) |
| VHL mutation | |||
| Wild type | 18 (17.1) | 28 (25.5) | 186 (42.2) |
| Alteration | 47 (44.8) | 82 (74.5) | 233 (52.8) |
| Not reported | 40 (38.1) | — | 22 (5.0) |
| Diabetes status | |||
| No | 76 (72.4) | NA | NA |
| Yes | 29 (27.6) | NA | NA |
| Not reported | — | 110 | 441 |
Abbreviations: ccRCC, clear cell renal cell carcinoma; CPTAC-3, Clinical Proteomic Tumor Analysis Consortium 3; NA, not available; TCC, Total Cancer Care Protocol; TCGA-KIRC, The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma; yr, years.